prellis
With $35M Bioprinting Investment Prellis Biologics Takes on New CEO
Organ bioprinting startup Prellis Biologics raised $35 million in a Series C round and plans to use the fresh capital to expand its proprietary, first-in-class human immune system-based drug discovery…
Featured
Prellis Biologics Secures $14.5M for Bioprinted Lymph Node
Prellis Biologics secured a $14.5 million series B round lead by Celesta Capital with existing shareholders Khosla Ventures. Prellis has an Externalized Immune System (EXIS) platform which allows researchers to discover…
Prellis Biologics Pursues Bioprinted Lymph Nodes for Production of COVID-19 Antibodies
Bay Area bioprinting firm Prellis Biologics is researching the use of bioprinted lymph nodes for the production of SARS-CoV-2 antibodies. The idea of using antibodies as a form of preventing…
